Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?

Abstract

Please cite this article as: { doi: https://doi.org/ This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Research Advances in Electrochemical Synthesis of Spirocyclic Skeleton Compounds

“…Compounds containing spirocyclopropane structural units exist in many synthetic and natural compounds, and many spirocyclopropanes have antitumor and antiviral activities. For example, ledipasvir is a drug used to treat hepatitis C. 10 In 2000, the Elinson group reported that the electrochemical Wideqvist reaction of malononitrile (1) and carbonyl compounds 2 using sodium bromide as the electro-lyte and ethanol as the solvent gave tetracyanocyclopropanes 3 (Scheme 1). 11 When the carbonyl compound was cyclohexanone (2a), the final product was the pyrroline spirocyclic compound 4.…”